$SRXH

UC Davis has been activated as a clinical trial site for CER-1236, an experimental cancer treatment, and will also serve as its primary manufacturing site. This is expected to expand patient recruitment and streamline logistics. SRX Global (SRXH) announced this milestone, which follows its agreement to acquire CERo Therapeutics (CERO). Preliminary trial results show no severe adverse events, but are not yet sufficient to establish safety or efficacy.

SRX Global Inc. (SRXH) invested $2.5 million in a multi-strategy trading platform fund, a joint venture with 5T Trading and its EMJX division. The platform aims to support proprietary traders, with SRXH's CEO and EMJX President highlighting the strategic value and potential for significant returns.

Neogen (NEOG) reported Q1 FY27 revenue up 6.5% to $222.8M, raised full-year guidance, but shares fell 3.7%. Penguin Solutions (PENG) beat Q4 estimates, raised FY27 outlook, shares up 13.9%. Constellation Brands (STZ) topped Q2 estimates, shares up 3.5%. Hess Midstream (HESM) shares dropped 10.3% after restructuring deal with Chevron (CVX) and lowered 2027 outlook. SRX Global (SRXH) shares rose 4% after $1M stock deal to acquire CERo Therapeutics.

SRX Global (SRXH) will acquire CERo Therapeutics, a cellular immunotherapy company, to accelerate development of CER-1236 for blood cancers. The deal combines SRX's public infrastructure with CERo's oncology platform, aiming to enhance capital access and operational resources. CER-1236 is in Phase 1 trials, with preliminary data showing no dose-limiting toxicities in recent cohorts. The transaction is subject to closing conditions and regulatory approvals.

SRX Global agreed to acquire CERo Therapeutics from CERo Therapeutics Holdings. The deal includes $1M in stock, $8.25M in debt forgiveness, and assuming $1.56M in liabilities. The companies also extended a note's maturity to align with the transaction timeline.

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Stock Purchase Agreement On October 6, 2026, SRX Global Inc., a Delaware corporation formerly known as SRx Health Solutions, Inc. (the “Company” or “SRX”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) wi

SRX Global allocated $1.5M to debut AI-driven ETFs on EMJX, with the first offering a digital asset hedging strategy. Eric Jackson will manage the ETFs, and Kupa AI will handle launch logistics. The ETFs are expected to launch in Q1 2027, with SRX planning to distribute holdings to shareholders. According to an SEC filing.

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered b

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (“Buye

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t